Effect of JS001, a monoclonal antibody targeting programed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial

Authors :: Shiyu Jiang
Jianliang Yang
Yan Sun
Ying Han
Shuxiang Zhang
Hui Feng
Yan Qin
Sheng Yao
Peng Liu
Xiaohong Han
Jiarui Yao
Zhishang Zhang
Yuankai Shi
Sheng Yang
Source :: Journal of Clinical Oncology. 36:11572-11572
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 11572Background: Alveolar soft part sarcoma (ASPS) is a rare and lethal malignancy mainly affecting youth, with no effective standard systemic treatment. Checkpoint inhibitors has showed efficacy i...

Tools